3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
204
Neoplasms
119
Breast Neoplasms
110
Colorectal Neoplasms
97
Ovarian Neoplasms
78
Prostatic Neoplasms
77
Neoplasm Metastasis
76
Multiple Myeloma
65
Lung Neoplasms
62
Squamous Cell Carcinoma of Head and Neck
51
Recurrence
49
Endometrial Neoplasms
47
Pancreatic Neoplasms
46
Stomach Neoplasms
42
Small Cell Lung Carcinoma
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Carcinoma, Renal Cell
41
Melanoma
37
Lymphoma, Non-Hodgkin
33
Leukemia, Myeloid, Acute
33
Triple Negative Breast Neoplasms
32
Urinary Bladder Neoplasms
29
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Lymphoma, Follicular
29
Lymphoma, Large B-Cell, Diffuse
28
Carcinoma, Hepatocellular
28
Head and Neck Neoplasms
26
Advanced Solid Tumors
25
Esophageal Neoplasms
24
Lymphoma
23
Interventions
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
30 days
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled